Vasoconstrictor use in liver transplantation: Is there evidence for rational use?

Minerva Gastroenterologica e Dietologica

Volumn 56, Issue 3, 2010, Pages 279-295

  Skagen, C L ^a   Said, A ^a  

^a UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

Author keywords

Hypertension, portal; Liver transplantation; Vasoconstrictor agents

Indexed keywords

ALBUMIN; ALPHA ADRENERGIC RECEPTOR STIMULATING AGENT; DOPAMINE; HYDROCORTISONE; HYPERTENSIVE FACTOR; METHYLENE BLUE; MIDODRINE; NORADRENALIN; OCTREOTIDE; PHENYLEPHRINE; PLACEBO; SOMATOSTATIN; TERLIPRESSIN; VASOACTIVE AGENT; VASOCONSTRICTOR AGENT; VASOPRESSIN;

ABDOMINAL BLEEDING; BLEEDING; BLOOD TRANSFUSION; COLD ISCHEMIA; CONTINUOUS INFUSION; DISEASE SEVERITY; DRUG HALF LIFE; END STAGE LIVER DISEASE; ENDOSCOPIC THERAPY; GRAFT SURVIVAL; HEART FUNCTION; HEMODYNAMIC MONITORING; HEMODYNAMICS; HEPATORENAL SYNDROME; HOSPITALIZATION; HUMAN; HYPEREMIA; KIDNEY BLOOD FLOW; KIDNEY FAILURE; KIDNEY FUNCTION; LIVER CIRRHOSIS; LIVER DISEASE; LIVER TRANSPLANTATION; LUNG EDEMA; META ANALYSIS (TOPIC); ORGAN PERFUSION; OXYGENATION; PORTAL HYPERTENSION; PORTAL VEIN BLOOD PRESSURE; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SCLEROTHERAPY; SEPSIS; SEPTIC SHOCK; SIDE EFFECT; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT; VARICEAL HEMORRHAGE; VASOCONSTRICTION;

END STAGE LIVER DISEASE; HEPATORENAL SYNDROME; HUMANS; HYPERTENSION, PORTAL; LIVER CIRRHOSIS; LIVER TRANSPLANTATION; RISK FACTORS; TREATMENT OUTCOME; VASOCONSTRICTOR AGENTS;

EID: 79251520313     PISSN: 00264776     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (81)

1. Skagen C, Lucey M, Said A. Liver transplantation: an update 2009. Curr Opin Gastroenterol 2009;25:202-8.
2. Wagener G, Gubitosa G, Renz J, Kinkhabwala M, Brentjens T, Guarrera JV et al. Vasopressin decreases portal vein pressure and flow in the native liver during liver transplantation. Liver Transpl 2008;14:1664-70.
3. Hennenberg M, Trebicka J, Sauerbruch T, Kohistani AZ, Heller J, Sauerbruch T. Mechanisms of extrahepatic vasodilation in portal hypertension. Gut. 200857: 1300-14.
4. Sanyal AJ, Bosch J, Blei A, Arroyo V. Portal hypertension and its complications. Gastroenterology 2008;134: 1715-28. (Pubitemid 351626956)
5. Stadibauer V, Wright GA, Banaji M, Mukhopadhya A, Mookerjee RP, Moore K et al. Relationship between activation of the sympathetic nervous system and renal blood flow autoregulation in cirrhosis. Gastroenterology 2008;134:111-9.
6. Ma Z, Lee SS. Cirrhotic cardiomyopathy: getting to the heart of the matter. Hepatology 1996;24:451-9.
7. Pozzi M, Carugo S, Boari G, Pecci V, de Ceglia S, Maggiolini S et al. Evidence of functional and structural cardiac abnormalities in cirrhotic patients with and without ascites. Hepatology 1997;26:1131-7.
8. Ruiz-del-Arbol L, Monescillo A, Arocena C, Valer P, Ginès P, Moreira V et al. Circulatory function and hepatorenal syndrome in cirrhosis. Hepatology 2005;42: 439-47. (Pubitemid 41061097)
9. Tsai MH, Peng YS, Chen YC, Liu NJ, Ho YP, Fang JT et al. Adrenal insufficiency in patients with cirrhosis, severe sepsis and septic shock. Hepatology 2006;43: 673-81.
10. Krag A, Bendtsen F, Mortensen C, Henriksen JH, Møller S. Effects of a single terlipressin administration on cardiac function and perfusion in cirrhosis. Eur J Gastroenterol Hepatol 2010 May 5. [Epub ahead of print].
11. Foreman MG, Mannino DM, Moss M. Cirrhosis as a risk factor for sepsis and death: analysis of the National Hospital Discharge Survey. Chest 2003;124:1016-20.
12. Plessier A, Denninger MH, Consigny Y, Pessione F, Francoz C, Durand F et al. Coagulation disorders in patients with cirrhosis and severe sepsis. Liver Int 2003;23:440-8.
13. Gustot T, Durand F, Lebrec D, , Vincent JL, Moreau R et al. Severe sepsis in cirrhosis. Hepatology 2009;50: 2022-33.
14. Ruiz-del-Arbol L, Urman J, Fernandez J, González M, Navasa M, Monescillo A et al. Systemic, renal, and hepatic hemodynamic derangement in cirrhotic patients with spontaneous bacterial peritonitis. Hepatology 2003;38:1210-8.
15. Albillos A, Rossi I, Cacho G, Martínez MV, Millán I, Abreu L et al. Enhanced endothelium-dependent vasodilation in patients with cirrhosis. Am J Physiol 1995;268(3 Pt 1):G459-64.
16. Dellinger RP, Levy MM, Carlet JM, Bion J, Parker MM, Jaeschke R et al Surviving Sepsis Campaign: international guidelines for management of severe sepsis and septic shock: 2008. Crit Care Med 2008;36:296-327.
17. Fernandez J, Escorsell A, Zabalza M, Fernández J, Escorsell A, Zabalza M, Felipe V, Navasa M, Mas A et al. Adrenal insufficiency in patients with cirrhosis and septic shock: Effect of treatment with hydrocortisone on survival. Hepatology 2006;44:1288-95.
18. Imperiale TF, Teran JC, McCullough AJ. A meta-analysis of somatostatin versus vasopressin in the management of acute esophageal variceal hemorrhage. Gastroenterology 1995;109:1289-94.
19. D'Amico G, Pagliaro L, Pietrosi G, Tarantino I. Emergency sclerotherapy versus vasoactive drugs for bleeding oesophageal varices in cirrhotic patients. Cochrane Database Syst Rev;3:CD002233.
20. Ioannou G, Doust J, Rockey DC. Terlipressin for acute esophageal variceal hemorrhage. Cochrane Database Syst Rev 2003:CD002147.
21. Abid S, Jafri W, Hamid S, Salih M, Azam Z, Mumtaz K et al. Terlipressin vs. octreotide in bleeding esophageal varices as an adjuvant therapy with endoscopic band ligation: a randomized double-blind placebo-controlled trial. Am J Gastroenterol 2009;104:617-23.
22. Baik SK, Jeong PH, Ji SW, Yoo BS, Kim HS, Lee DK et al. Acute hemodynamic effects of octreotide and terlipressin in patients with cirrhosis: a randomized comparison. Am J Gastroenterol 2005;100:631-5.
23. Ginès P, Guevara M, Arroyo V, Rodés J. Hepatorenal syndrome. Lancet 2003;362:1819-27.
24. Duvoux C, Zanditenas D, Hézode C, Chauvat A, Monin JL, Roudot-Thoraval F et al. Effects of noradrenalin and albumin in patients with type I hepatorenal syndrome: a pilot study. Hepatology 2002;36:374-80. (Pubitemid 34810356)
25. Pomier-Layrargues G, Paquin SC, Hassoun Z, Lafortune M, Tran A et al. Octreotide in hepatorenal syndrome: a randomized, double-blind, placebo-controlled, crossover study. Hepatology 2003;38:238-43.
26. Angeli P, Volpin R, Gerunda G, Craighero R, Roner P, Merenda R et al. Reversal of type 1 hepatorenal syndrome with the administration of midodrine and octreotide. Hepatology 1999;29:1690-7.
27. Wong F, Pantea L, Sniderman K. Midodrine, octreotide, albumin, and TIPS in selected patients with cirrhosis and type 1 hepatorenal syndrome. Hepatology 2004;40:55-64.
28. Skagen C, Einstein M, Lucey MR, Said A. Combination treatment with octreotide, midodrine, and albumin improves survival in patients with type 1 and type 2 hepatorenal syndrome. J Clin Gastroenterol 2009;43:680-5.
29. Hadengue A, Gadano A, Moreau R, Giostra E, Durand F, Valla D et al. Beneficial effects of the 2-day administration of terlipressin in patients with cirrhosis and hepatorenal syndrome. J Hepatol 1998;29:565-70.
30. Gluud LL, Kjaer MS, Christensen E. Terlipressin for hepatorenal syndrome. Cochrane Database Syst Rev 2006:CD005162.
31. Neri S, Pulvirenti D, Malaguarnera M, Cosimo BM, Bertino G, Ignaccolo L et al. Terlipressin and albumin in patients with cirrhosis and type I hepatorenal syndrome. Dig Dis Sci 2008;53:830-5.
32. Martin-Llahi M, Pepin MN, Guevara M, Díaz F, Torre A, Monescillo A et al. Terlipressin and albumin vs albumin in patients with cirrhosis and hepatorenal syndrome: a randomized study. Gastroenterology 2008;134:1352-9.
33. Sanyal AJ, Boyer T, Garcia-Tsao G, Regenstein F, Rossaro L, Appenrodt B et al. A randomized, prospective, double-blind, placebo-controlled trial of terlipressin for type 1 hepatorenal syndrome. Gastroenterology. 2008;134:1360-8.
34. Sagi SV, Mittal S, Kasturi KS, Sood GK. Terlipressin therapy for reversal of type 1 hepatorenal syndrome: A meta-analysis of randomized controlled trials. J Gastroenterol Hepatol.
35. Nazar A, Pereira GH, Guevara M, Martin-Llahi M, Pepin MN, Marinelli M et al. Predictors of response to therapy with terlipressin and albumin in patients with cirrhosis and type 1 hepatorenal syndrome. Hepatology ;51:219-26.
36. Alessandria C, Venon WD, Marzano A, Barletti C, Fadda M, Rizzetto M. Renal failure in cirrhotic patients: role of terlipressin in clinical approach to hepatorenal syndrome type 2. Eur J Gastroenterol Hepatol 2002;14: 1363-8. (Pubitemid 36054926)
37. Uriz J, Ginès P, Cárdenas A, Sort P, Jiménez W, Salmerón JM et al. Terlipressin plus albumin infusion: an effective and safe therapy of hepatorenal syndrome. J Hepatol 2000;33:43-8.
38. Ortega R, Ginès P, Uriz J, Cárdenas A, Calahorra B, De Las Heras D et al. Terlipressin therapy with and without albumin for patients with hepatorenal syndrome: results of a prospective, nonrandomized study. Hepatology 2002;36(4 Pt 1):941-8.
39. Massicotte L, Lenis S, Thibeault L, Sassine MP, Seal RF, Roy A. Effect of low central venous pressure and phlebotomy on blood product transfusion requirements during liver transplantations. Liver Transpl 2006;12: 117-23.
40. Massicotte L, Perrault MA, Denault AY, Klinck JR, Beaulieu D, Roy JD et al. Effects of phlebotomy and phenylephrine infusion on portal venous pressure and systemic hemodynamics during liver transplantation. Transplantation 2010;89:920-7.
41. Amador A, Grande L, Marti J, Marti J, Deulofeu R, Miquel R, Sola A et al. Ischemic pre-conditioning in deceased donor liver transplantation: a prospective randomized clinical trial. Am J Transplant 2007;7: 2180-9. (Pubitemid 47247061)
42. Xia VW, Fond A, Du B. Ascites, but not hyponatremia, is associated with high intraoperative transfusion and vasopressor requirements during liver transplantation. Transplant Proc 2006;38:1398-9. (Pubitemid 43912757)
43. Xia VW, Du B, Braunfeld M, Neelakanta G, Hu KQ, Nourmand H et al. Preoperative characteristics and intraoperative transfusion and vasopressor requirements in patients with low vs. high MELD scores. Liver Transpl 2006;12:614-20.
44. Hoffmann K, Weigand MA, Hillebrand N, Büchler MW, Schmidt J, Schemmer P et al. Is veno-venous bypass still needed during liver transplantation? A review of the literature. Clin Transplant 2009;23:1-8.
45. Lerut J, Ciccarelli O, Roggen F, Laterre PF, Danse E, Goffette P et al. Cavocaval adult liver transplantation and retransplantation without venovenous bypass and without portocaval shunting: a prospective feasibility study in adult liver transplantation. Transplantation 2003;75:1740-5.
46. Zaballos JM, Riaño D, Dávila PA, Pérez-Cerdá F, Martínez PA. Venovenous bypass vs no bypass in orthotopic liver transplantation: metabolic values during reperfusion. Transplant Proc 1993;25:1865-6.
47. Moreno-Gonzalez E, Meneu-Diaz JG, Fundora Y, Ortega P, Moreno Elola-Olaso A et al. Advantages of the piggy back technique on intraoperative transfusion, fluid compsumption, and vasoactive drugs requirements in liver transplantation: a comparative study. Transplant Proc 2003;35:1918-9.
48. Acosta F, Sansano T, Robles R, Contreras RF, Reche M, Beltran R et al. Hemodynamic consequences of portal and lateral clamping of the inferior vena cava during liver transplantation. Transplant Proc 1999;31:2413-4. (Pubitemid 29433980)
49. Hadengue A, Moreau R, Gaudin C, Bacq Y, Champigneulle B, Lebrec D. Total effective vascular compliance in patients with cirrhosis: a study of the response to acute blood volume expansion. Hepatology 1992;15:809-15.
50. Moller S, Bendtsen F, Henriksen JH. Effect of volume expansion on systemic hemodynamics and central and arterial blood volume in cirrhosis. Gastroenterology 1995;109:1917-25.
51. Safdar N, Dezfulian C, Collard HR, Bacq Y, Champigneulle B, Lebrec D. Clinical and economic consequences of ventilator-associated pneumonia: a systematic review. Crit Care Med 2005;33:2184-93.
52. Salcedo A, Garijo J, Monge L, Fernández N, García- Villalón AL, Turrión VS et al. Adrenergic response of splanchnic arteries from cirrhotic patients: role of nitric oxide, prostanoids, and reactive oxygen species. Exp Biol Med (Maywood) 2007;232:1360-7.
53. Vaughan RB, Angus JA, Angus PW. Vasoconstrictor responses are normal but prostanoid-mediated vasodilatation is enhanced in human cirrhotic mesenteric arteries. J Gastroenterol Hepatol 2005;20:1158-64.
54. Vaughan RB, Angus PW, Chin-Dusting JP. Evidence for altered vascular responses to exogenous endothelin-1 in patients with advanced cirrhosis with restoration of the normal vasoconstrictor response following successful liver transplantation. Gut 2003;52:1505-10.
55. Zipprich A, Steudel N, Behrmann C, Meiss F, Sziegoleit U, Fleig WE et al. Functional significance of hepatic arterial flow reserve in patients with cirrhosis. Hepatology 2003;37:385-92. (Pubitemid 36152538)
56. Yagi S, Iida T, Taniguchi K, Hori T, Hamada T, Fujii K et al. Impact of portal venous pressure on regeneration and graft damage after living-donor liver transplantation. Liver Transpl 2005;11:68-75. (Pubitemid 40124444)
57. Martikainen TJ, Tenhunen JJ, Uusaro A, Ruokonen E. The effects of vasopressin on systemic and splanchnic hemodynamics and metabolism in endotoxin shock. Anesth Analg 2003;97:1756-63. (Pubitemid 37475134)
58. Ponnudurai RN, Koneru B, Akhtar SA, Wachsberg RH, Fisher A, Wilson DJ et al. Vasopressor administration during liver transplant surgery and its effect on endotracheal reintubation rate in the postoperative period: a prospective, randomized, double-blind, placebo-controlled trial. Clin Ther 2005;27:192-8.
59. Cabezuelo JB, Ramirez P, Rios A, Acosta F, Torres D, Sansano T et al. Risk factors of acute renal failure after liver transplantation. Kidney Int 2006;69:1073-80.
60. Richer M, Robert S, Lebel M. Renal hemodynamics during norepinephrine and low-dose dopamine infusions in man. Crit Care Med 1996;24:1150-6.
61. Martin C, Papazian L, Perrin G, Saux P, Gouin F. Norepinephrine or dopamine for the treatment of hyperdynamic septic shock? Chest 1993;103:1826-31.
62. Martin C, Viviand X, Arnaud S, Vialet R, Rougnon T. Effects of norepinephrine plus dobutamine or norepinephrine alone on left ventricular performance of septic shock patients. Crit Care Med 1999;27:1708-13.
63. Martin C, Viviand X, Leone M, Vialet R, Rougnon T. Effect of norepinephrine on the outcome of septic shock. Crit Care Med 2000;28:2758-65.
64. Karzai W, Reilly JM, Hoffman WD, Cunnion RE, Danner RL, Banks SM et al. Hemodynamic effects of dopamine, norepinephrine, and fluids in a dog model of sepsis. Am J Physiol 1995;268(2 Pt 2):H692-702.
65. Anderson WP, Korner PI, Selig SE. Mechanisms involved in the renal responses to intravenous and renal artery infusions of noradrenaline in conscious dogs. J Physiol 1981;321:21-30.
66. Zhang LP, Li M, Yang L. Effects of different vasopressors on hemodynamics in patients undergoing orthotopic liver transplantation. Chin Med J (Engl). 2005;118:1952-8.
67. Alessandria C, Ottobrelli A, Debernardi-Venon W, Todros L, Cerenzia MT, Martini S et al. Noradrenalin vs terlipressin in patients with hepatorenal syndrome: a prospective, randomized, unblinded, pilot study. J Hepatol. 2007;47:499-505. (Pubitemid 47331744)
68. Moreau R, Asselah T, Condat B, de Kerguenec C, Pessione F, Bernard B et al. Comparison of the effect of terlipressin and albumin on arterial blood volume in patients with cirrhosis and tense ascites treated by paracentesis: a randomised pilot study. Gut 2002;50:90-4. (Pubitemid 34028309)
69. Molenaar IQ, Warnaar N, Groen H, Tenvergert EM, Slooff MJ, Porte RJ. Efficacy and safety of antifibrinolytic drugs in liver transplantation: a systematic review and meta-analysis. Am J Transplant 2007;7:185-94.
70. Pereboom IT, de Boer MT, Haagsma EB, Hendriks HG, Lisman T, Porte RJ. Platelet transfusion during liver transplantation is associated with increased postoperative mortality due to acute lung injury. Anesth Analg 2009;108:1083-91.
71. de Boer MT, Christensen MC, Asmussen M, van der Hilst CS, Hendriks HG, Slooff MJ et al. The impact of intraoperative transfusion of platelets and red blood cells on survival after liver transplantation. Anesth Analg 2008;106:32-44.
72. Ramos E, Dalmau A, Sabate A, Lama C, Llado L, Figueras J et al. Intraoperative red blood cell transfusion in liver transplantation: influence on patient outcome, prediction of requirements, and measures to reduce them. Liver Transpl 2003;9:1320-7.
73. Boyd SD, Stenard F, Lee DK, Goodnough LT, Esquivel CO, Fontaine MJ. Alloimmunization to red blood cell antigens affects clinical outcomes in liver transplant patients. Liver Transpl 2007;13:1654-61.
74. Schroeder RA, Collins BH, Tuttle-Newhall E, Robertson K, Plotkin J, Johnson LB et al. Intraoperative fluid management during orthotopic liver transplantation. J Cardiothorac Vasc Anesth 2004;18:438-41.
75. Koelzow H, Gedney JA, Baumann J, Snook NJ, Bellamy MC. The effect of methylene blue on the hemodynamic changes during ischemia reperfusion injury in orthotopic liver transplantation. Anesth Analg 2002;94:824-9, table of contents.
76. Marik PE, Gayowski T, Starzl TE. The hepatoadrenal syndrome: a common yet unrecognized clinical condition. Crit Care Med 2005;33:1254-9.
77. Kostopanagiotou G, Pandazi A, Arkadopoulos N, Theodoraki K, Mystakidou K, Costopanagiotou C et al. Norepinephrine in small-for-size liver grafts: an experimental study in pigs. J Surg Res 2007;141:257-61.
78. Mehrabi A, Golling M, Kashfi A, Boucsein T, Schemmer P, Gutt CN et al. Negative impact of systemic catecholamine administration on hepatic blood perfusion after porcine liver transplantation. Liver Transpl 2005;11:174-87. (Pubitemid 40268215)
79. Krarup N. The effect of noradrenaline and adrenaline on hepatosplanchnic hemodynamics, functional capacity of the liver and hepatic metabolism. Acta Physiol Scand 1973;87:307-19.
80. Marsh JW, Drougas JG, Wright JK, Chapman WC, Becker YT, Barnard SE et al. The effect of low dose epinephrine infusion on hepatic hemodynamics. Transplant Proc 1998;30:2306-8.
81. Restuccia T, Ortega R, Guevara M, Ginès P, Alessandria C, Ozdogan O et al. Effects of treatment of hepatorenal syndrome before transplantation on posttransplantation outcome. A case-control study. J Hepatol 2004;40:140-6.